Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cicletanine SCHEMBL29915570 | 0.86 | MEN1 (0.36) | KDM4EMEN1CYP1A2CYP2D6CYP2C19 | |
| Cicletanine SCHEMBL637073 | 0.86 | MEN1 (0.36) | KDM4EMEN1CYP1A2CYP2D6CYP2C19 | |
| Cicletanine SCHEMBL6060344 | 0.86 | MEN1 (0.36) | KDM4EMEN1CYP1A2CYP2D6CYP2C19 | |
| Cicletanine SCHEMBL16859315 | 0.86 | MEN1 (0.36) | KDM4EMEN1CYP1A2CYP2D6CYP2C19 | |
| Cicletanine SCHEMBL49794 | 0.86 | MEN1 (0.36) | KDM4EMEN1CYP1A2CYP2D6CYP2C19 | |
| Cicletanine SCHEMBL637385 | 0.86 | MEN1 (0.36) | KDM4EMEN1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL10830702 | 0.86 | CYP2D6 (0.38) | KDM4EMEN1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL11135868 | 0.85 | MEN1 (0.34) | KDM4EMEN1CYP1A2CYP2D6CYP2C19 | |
| Cicletanine SCHEMBL387011 | 0.85 | KDM4E (0.35) | KDM4EMEN1CYP1A2CYP2D6CYP2C19 | |
| Cicletanine SCHEMBL29633447 | 0.85 | KDM4E (0.35) | KDM4EMEN1CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2167082-A1 | COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS | Gilead Sciences, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| EP-1951264-A4 | USE OF CICLETANINE AND OTHER FUROPYRIDINES FOR TREATMENT OF HYPERTENSION | NAVITAS PHARMA INC (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2009012223-A1 | COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS | GILEAD SCIENCES, INC. (US) | 2009-01-22 | — | — | WO | disclosed |
| EP-1951264-A2 | USE OF CICLETANINE AND OTHER FUROPYRIDINES FOR TREATMENT OF HYPERTENSION | Navitas Pharma, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070141174-A1 | Enantiomeric compositions of cicletanine, in combination with other agents, for the treatment of hypertension | NAVITAS PHARMA, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| WO-2007056454-A2 | USE OF CICLETANINE AND OTHER FUROPYRIDINES FOR TREATMENT OF HYPERTENSION | NAVITAS PHARMA (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105817-A1 | Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension | GILEAD SCIENCES, INC. | 2007-05-10 | — | — | US | disclosed |
| WO-2006128035-A2 | ENANTIOMERIC COMPOSITIONS OF CICLETANINE, IN COMBINATION WITH OTHER AGENTS, FOR THE TREATMENT OF HYPERTENSION | NAVITAS PHARMA, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-4569938-A | Diuretic, antihypertensive and antihistaminic 7-carboxymethoxy-furo-(3,4-c)-pyridine derivatives | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 1986-02-11 | — | — | US | disclosed |